Vertex Pharmaceuticals demonstrates resilience with robust CF franchise, new approvals, and diversification efforts. Read why ...

Vertex Pharma (VRTX) stock slips as UnitedHealth (UNH) offers its pain drug Journavx Tier 3 coverage, setting a rivalry with ...

Positive data from a pair of acute pain studies convinced the company that its drug, which works differently than existing ...

Tris Pharma’s opioid alternative has scored a third win in a trio of clinical trials, providing the biotech with the data ...

Tris Pharma previously announced data from another Phase III trial of cebranopadol, which also met its primary endpoint.

Optum, the pharmacy benefit manager owned by UnitedHealth Group, placed Journavx on some of its commercial formularies in an ...

The stock's fall snapped a four-day winning streak.

Bernstein analyst William Pickering maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report) yesterday and set a price ...

Vertex Pharmaceuticals’ (VRTX) non-opioid pain drug Journavx was picked up by UnitedHealth’s (UNH) Optum on “Tier 3.” The insurer said, ...

Marty Makary, Trump’s pick for FDA commissioner, testifies before the Senate health committee on Thursday. In 2021, Marty ...

A U.S. federal judge has refused to allow compounding pharmacies to keep making copies of Eli Lilly's popular weight-loss and ...

Dr. Marty Makary will testify before the Senate health committee on Thursday. Lawmakers may press him over staff reductions ...